Detalles de la búsqueda
1.
FDA Approval Summary: Ruxolitinib for Treatment of Chronic Graft-Versus-Host Disease after Failure of One or Two Lines of Systemic Therapy.
Oncologist
; 27(6): 493-500, 2022 06 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35363318
2.
Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
Lancet Oncol
; 22(9): 1230-1239, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34310904
3.
Oncology Expanded Access and FDA's Project Facilitate.
Oncologist
; 26(10): e1880-e1882, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34288259
4.
Benefit-Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based Chemotherapy.
Oncologist
; 26(4): 318-324, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33345396
5.
FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib.
Oncologist
; 26(9): 797-806, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33973307
6.
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health.
Oncologist
; 26(10): e1786-e1799, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34196068
7.
FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer.
Oncologist
; 26(5): 433-438, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33687763
8.
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA-Mutated Metastatic Castrate-Resistant Prostate Cancer.
Oncologist
; 26(2): 139-146, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33145877
9.
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Lancet Oncol
; 21(2): 250-260, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31859246
10.
FDA Accelerated Approval of Pembrolizumab for Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma.
Oncologist
; 25(7): e1077-e1082, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32272501
11.
FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.
Oncologist
; 25(2): e328-e334, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32043777
12.
Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public Workshop.
J Urol
; 203(1): 115-119, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31502940
13.
Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy.
Curr Oncol Rep
; 22(11): 116, 2020 08 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-32851542
14.
FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.
Oncologist
; 24(1): 103-109, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30120163
15.
FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.
Oncologist
; 24(4): 563-569, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30541754
16.
Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis.
Lancet Oncol
; 19(2): 229-239, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29361469
17.
FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia.
Oncologist
; 23(11): 1366-1371, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30018129
18.
FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma.
Oncologist
; 23(6): 734-739, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29438096
19.
FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the BRAFV600 Mutation.
Oncologist
; 23(12): 1520-1524, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30120160
20.
FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations.
Oncologist
; 23(6): 740-745, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29438093